{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Ruggiero R"],"pubmed_abstract":["Immune checkpoint inhibitors (ICIs) are widely used improving clinical outcomes in many cancer patients. However, they can induce serious consequences, like neurological immune-related adverse drug reactions (NirADRs). Although these are rare complications, they can be serious with important impact on patients' quality of life. Our purpose is to describe these adverse events observed in the European clinical practice context. We carried out a descriptive analysis of individual case safety reports (ICSRs) related to ICIs collected until February 7, 2020, in the European spontaneous reporting database, EudraVigilance, and reported nervous disorders as suspect adverse drug reactions (ADRs). NirADRs were classified according to the Medical Dictionary for Regulatory Activities (MedDRA). In orde"],"journal":["Frontiers in oncology"],"pagination":["824511"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8964934"],"repository":["biostudies-literature"],"pubmed_title":["Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data."],"pmcid":["PMC8964934"],"pubmed_authors":["Rossi F","Fraenza F","Sportiello L","Capuano A","Ruggiero R","Stelitano B","Scavone C","di Mauro G","Danesi R","Di Napoli R","Rafaniello C","Del Re M"],"additional_accession":[]},"is_claimable":false,"name":"Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data.","description":"Immune checkpoint inhibitors (ICIs) are widely used improving clinical outcomes in many cancer patients. However, they can induce serious consequences, like neurological immune-related adverse drug reactions (NirADRs). Although these are rare complications, they can be serious with important impact on patients' quality of life. Our purpose is to describe these adverse events observed in the European clinical practice context. We carried out a descriptive analysis of individual case safety reports (ICSRs) related to ICIs collected until February 7, 2020, in the European spontaneous reporting database, EudraVigilance, and reported nervous disorders as suspect adverse drug reactions (ADRs). NirADRs were classified according to the Medical Dictionary for Regulatory Activities (MedDRA). In orde","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-05-18T12:07:36.5Z","creation":"2025-05-18T12:07:36.5Z"},"accession":"S-EPMC8964934","cross_references":{"pubmed":["35372076"],"doi":["10.3389/fonc.2022.824511"]}}